Algert Global LLC Tcr2 Therapeutics Inc. Transaction History

Algert Global LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $66,230 - $129,977	-27,596 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $112,594 - $205,030	-24,584 Reduced 47.11%	27,596 $129,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $349,061 - $758,919	41,358 Added 382.17%	52,180 $444,000
Q2 2021 Aug 13, 2021	BUY	$16.41 - $24.71 $177,589 - $267,411	10,822 New	10,822 $178,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.